Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700010028

Next Previous
X
Search
Trial Profile

Clinical Trials Insight: 700010028

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2008

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mifamurtide (Primary) ; Cisplatin; Doxorubicin; Ifosfamide; Methotrexate
  • Indications Osteosarcoma
  • Focus Registrational; Therapeutic Use
  • Sponsors IDM Pharma

    • Most Recent Events

    • 22 Jul 2008 Results for 91 patients with metastatic disease reported at ASCO 2008.
    • 01 Jul 2008 CHMP has requested additional data analyses on the phase III L-MTP-PE trial before it will offer an opinion on the MAA application. IDM expect an opinion in the third quater of 2008.
    • 02 Jun 2008 Results of a subgroup analysis presented at the Annual Meeting of the American Society of Clinical Oncology 2008 and an IDM Pharma media release (9089573).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top